Outlook Therapeutics, Inc.(OTLK)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,844 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
OTLK Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Outlook Therapeutics, Inc. (OTLK), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OTLK at 16.0/100 on a 32-signal composite quality model, placing it at rank #2,844 of 2,962 stocks — the bottom half of the AI-ranked universe. Top institutional holders of OTLK by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, PERCEPTIVE ADVISORS, MARSHALL WACE, LLP, based on the most recent SEC filings. OTLK trades on the Nasdaq exchange and files with the SEC under CIK 1649989. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OTLK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Outlook Therapeutics, Inc. directly from SEC EDGAR. Outlook Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 16 and 24 since 2026, currently 16.0 — a declining long-term trajectory across 9 quarterly and live scoring snapshots.
Net Income
Q2 2026
$-20.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+17.2% YoYOperating Income
+6.5% YoYEPS (Diluted)
+55.9% YoYTotal Assets
-35.5% YoYOp. Cash Flow
+24.7% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1.4M | — | — | — | — | — |
| Net Income | $-62.4M +17.2% | $-75.4M -27.8% | $-59.0M +10.7% | $-66.1M -24.2% | $-53.2M -50.9% | $-35.2M |
| Operating Income | $-67.1M +6.5% | $-71.7M -35.0% | $-53.1M +15.8% | $-63.1M -21.9% | $-51.7M -40.4% | $-36.8M |
| EPS (Diluted) | $-1.79 +55.9% | $-4.06 +14.0% | $-4.72 -1422.6% | $-0.31 +11.4% | $-0.35 +47.8% | $-0.67 |
| Total Assets | $18.6M -35.5% | $28.8M -10.8% | $32.3M +13.2% | $28.5M +25.1% | $22.8M +15.6% | $19.7M |
| Operating Cash Flow | $-51.8M +24.7% | $-68.8M -60.1% | $-43.0M +24.2% | $-56.7M -4.5% | $-54.3M -70.7% | $-31.8M |
Get alerted when OTLK's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Outlook Therapeutics, Inc. including:
Top Institutional Holders of OTLK
VANGUARD CAPITAL MANAGEMENT LLC
$7.0M4,376,872 shPERCEPTIVE ADVISORS LLC
$5.0M3,139,216 shMARSHALL WACE, LLP
$3.2M1,987,578 shBlackRock, Inc.
$2.7M1,668,579 shJANE STREET GROUP, LLC
$2.3M1,425,270 shGEODE CAPITAL MANAGEMENT, LLC
$2.0M1,245,868 shSUSQUEHANNA INTERNATIONAL GROUP, LLP
$1.5M968,190 shHRT FINANCIAL LP
$1.2M784,904 shVANGUARD FIDUCIARY TRUST CO
$1.1M661,664 shGILPIN WEALTH MANAGEMENT, LLC
$882.5K555,000 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $7.0M | 4,376,872 |
| PERCEPTIVE ADVISORS LLC | $5.0M | 3,139,216 |
| MARSHALL WACE, LLP | $3.2M | 1,987,578 |
| BlackRock, Inc. | $2.7M | 1,668,579 |
| JANE STREET GROUP, LLC | $2.3M | 1,425,270 |
| GEODE CAPITAL MANAGEMENT, LLC | $2.0M | 1,245,868 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.5M | 968,190 |
| HRT FINANCIAL LP | $1.2M | 784,904 |
| VANGUARD FIDUCIARY TRUST CO | $1.1M | 661,664 |
| GILPIN WEALTH MANAGEMENT, LLC | $882.5K | 555,000 |
More Healthcare Companies
View all Healthcare →Put OTLK on your watchlist
Track score changes the day Outlook Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is OTLK a good stock to buy?
13F Pro's AI-powered analysis of Outlook Therapeutics, Inc. (OTLK) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OTLK are available on the OTLK stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. OTLK is classified as a small company.
Which hedge funds own OTLK?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OTLK. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Outlook Therapeutics, Inc.'s investment landscape.